XML 56 R47.htm IDEA: XBRL DOCUMENT v3.22.2
Revenue, Credit Concentrations and Geographic Information - Disaggregates of Net Product Revenues by Product (Detail) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue from External Customer [Line Items]        
Revenue $ 533,798 $ 501,693 $ 1,053,157 $ 987,723
Product        
Revenue from External Customer [Line Items]        
Revenue 517,660 486,670 1,023,185 954,439
Vimizim | Marketed by Company        
Revenue from External Customer [Line Items]        
Revenue 173,206 171,655 356,265 329,953
Naglazyme | Marketed by Company        
Revenue from External Customer [Line Items]        
Revenue 115,783 118,813 243,814 226,149
Palynziq | Marketed by Company        
Revenue from External Customer [Line Items]        
Revenue 61,643 58,935 116,528 112,973
Kuvan | Marketed by Company        
Revenue from External Customer [Line Items]        
Revenue 57,602 78,807 116,939 149,570
Brineura | Marketed by Company        
Revenue from External Customer [Line Items]        
Revenue 37,725 30,332 73,898 57,657
Voxzogo | Marketed by Company        
Revenue from External Customer [Line Items]        
Revenue 34,374 0 54,032 0
Brineura, Kuvan, Naglazyme, Palynziq, and Vimizim | Marketed by Company        
Revenue from External Customer [Line Items]        
Revenue 480,333 458,542 961,476 876,302
Aldurazyme | Marketed by Sanofi        
Revenue from External Customer [Line Items]        
Revenue 37,327 28,128 61,709 78,137
Royalty and other revenues        
Revenue from External Customer [Line Items]        
Revenue $ 16,138 $ 15,023 $ 29,972 $ 33,284